| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 175.40 | 13582 |
| Intrinsic value (DCF) | 0.66 | -49 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 18.53 | 1345 |
NFL Biosciences SA is a pioneering French biotechnology company focused on developing natural addiction withdrawal solutions, particularly for smokers. Headquartered in Castelnau-le-Lez, France, the company specializes in botanical-based drug candidates aimed at treating tobacco addiction. Its flagship product, NFL-101, is a tobacco extract currently in Phase III clinical trials, targeting smoking cessation. Additionally, NFL Biosciences is advancing NFL-201, a cannabis and tobacco extract in preclinical stages, and NFL-301, a botanical extract derived from traditional Chinese medicine. Founded in 2006, the company operates in the high-growth biotechnology sector, leveraging natural compounds to address addiction—a significant unmet medical need. With no current revenue but a strong pipeline, NFL Biosciences represents an innovative player in the healthcare industry, particularly in smoking cessation therapies.
NFL Biosciences SA presents a high-risk, high-reward investment opportunity due to its focus on novel, natural addiction treatments. The company's lead candidate, NFL-101, is in Phase III trials, positioning it closer to potential commercialization. However, with no revenue and negative net income (-€2.08M in the latest period), the company relies heavily on clinical success and future funding. Its high beta (1.70) indicates significant volatility, typical of clinical-stage biotech firms. Investors should weigh the promising pipeline against the inherent risks of drug development, including regulatory hurdles and competition. The €12.3M market cap suggests speculative interest, making it suitable for risk-tolerant investors bullish on smoking cessation innovations.
NFL Biosciences competes in the smoking cessation and addiction treatment market, which includes both pharmaceutical and natural therapy providers. The company's competitive edge lies in its natural, botanical-based approach, differentiating it from synthetic nicotine replacement therapies (NRTs) like patches or gums. However, its pipeline is still in development, whereas competitors like Pfizer (Chantix) and GlaxoSmithKline (Nicorette) already have FDA-approved products. NFL Biosciences' focus on tobacco and cannabis extracts could appeal to patients seeking plant-derived alternatives, but clinical efficacy and safety data will be critical. The lack of revenue and reliance on trial outcomes make it vulnerable compared to larger, diversified biotech firms. Its small size allows agility in R&D but limits commercialization capabilities without partnerships.